<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820949</url>
  </required_header>
  <id_info>
    <org_study_id>380/12</org_study_id>
    <nct_id>NCT01820949</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients</brief_title>
  <acronym>PBM</acronym>
  <official_title>Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vifor Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate clinical outcome after the step-wise implementation of a Patient&#xD;
      Blood Management (PBM) Program in surgical patients at 4 hospitals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A PBM program will be implemented stepwise in four University Hospitals, with the intention&#xD;
      to optimize preoperative hemoglobin concentration of patients and to standardize transfusion&#xD;
      practice within hemotherapy. The PBM program includes 1) an algorithm with the aim to correct&#xD;
      preoperative anemia in elective surgery, 2) a strict indication for the transfusion of red&#xD;
      blood cells defined by the &quot;Cross-sectional Guidelines for Therapy with Blood Components and&#xD;
      Plasma Derivatives&quot; for all surgical patients, and 3) a perioperative checklist for different&#xD;
      blood-sparing techniques (e.g. cell-saver, normothermia, reduced blood samples, point-of-care&#xD;
      diagnostics for bedside coagulation management).&#xD;
&#xD;
      Primary endpoint: Safety of the use of PBM program will be determined by comparability of the&#xD;
      composite outcome (in-hospital myocardial infarction, stroke, acute renal failure, death of&#xD;
      any cause, pneumonia and sepsis until discharge from hospital) between patients treated after&#xD;
      implementation and patients treated before implementation (control cohort) of the PBM&#xD;
      program.&#xD;
&#xD;
      The primary composite endpoint defined as described above will be registered electronically&#xD;
      by analysis of Diagnosis Related Groups (DRG) codes. The frequency of these events will be&#xD;
      compared between PBM and control cohort stratified by center with a one-sided Mantel-Haenszel&#xD;
      test in a non-inferiority setting with significance level of α=2.5% and a non-inferiority&#xD;
      margin of 1% for the incidence of the composite endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsisComposite outcome</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
    <description>Composite endpoint defined as in-hospital myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsis until discharge from hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay on the intensive care unit</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of red blood cell transfusions during hospital stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of coagulation factors</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">110000</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Control cohort</arm_group_label>
    <description>Standard care before implementation (pre-implementation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBM cohort</arm_group_label>
    <description>After implementation of PBM program (post-implementation)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        all surgical patients over a period of 24 months at 4 hospitals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All non- ambulant, surgical, anesthetized patients (≥18 years)&#xD;
&#xD;
          -  General Surgery, Cardiac Surgery, Thoracic Surgery, Trauma Surgery, Vascular Surgery,&#xD;
             Urology, Gynecology, Otolaryngology, Neurosurgery, Crania-Maxillofacial Surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ambulant and all non-surgical anesthetic procedures&#xD;
&#xD;
          -  Surgery in the field of Dermatology or Ophthalmology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Zacharowski, MD, PhD, FRCA</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Meybohm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erhard Seifried, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Red Cross Blood Service Baden-Württemberg-Hessen, Institute for Transfusion Medicine and Immunohematology of the Goethe University Hospital, Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Herrmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Biostatistics and Mathematical Modeling, Goethe University Frankfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.biomedcentral.com/content/pdf/s12913-014-0576-3.pdf</url>
    <description>Safety and effectiveness of a Patient Blood Management (PBM) program in surgical patients - the study design for a multi-centre prospective epidemiologic non-inferiority trial</description>
  </link>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <last_update_submitted>September 4, 2015</last_update_submitted>
  <last_update_submitted_qc>September 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Professor Kai Zacharowski, M.D., Ph.D., FRCA</investigator_full_name>
    <investigator_title>Prof. Dr. Dr. Kai Zacharowski</investigator_title>
  </responsible_party>
  <keyword>patient blood management</keyword>
  <keyword>patients safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

